Use of the Perclose ProGlide suture-mediated closure strategy to achieve vascular access-site hemostasis after transfemoral TAVR results in fewer major vascular complications than does deployment of ...

LAS VEGAS, NV—Vascular closure complications occur in about one-quarter of patients undergoing transfemoral TAVR, according to post hoc analysis of the BRAVO 3 trial, but not all closure devices ...

A head-to-head comparison of vascular closure devices defied expectations in the CHOICE-CLOSURE trial. For large-bore arterial access site closure after transfemoral transcatheter aortic valve ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. LAS VEGAS — In a comparison of two vascular closure ...

LAS VEGAS (MAY 21, 2019) - Results from an analysis of a large randomized trial shows ProGlide vascular closure device (VCD) was associated with lower rates of vascular complications, lower rates of ...

Abbott Park, IL - Abbott Laboratories announced the launch of the next-generation Perclose ® suture-mediated vessel closure system, Perclose ProGlide TM, featuring a polypropylene monofilament suture.

LAS VEGAS -- Bleeding complication risk after transcatheter aortic valve replacement (TAVR) isn't the same between two of the most commonly used femoral vascular closure devices, one study showed, ...

Please provide your email address to receive an email when new articles are posted on . The CHOICE-CLOSURE trial was presented by Mohamed Abdel-Wahab, MD, consultant cardiologist and head of the ...

The plug-based Manta (Teleflex) device was associated with significantly more vascular complications than the suture-based ProGlide (Abbott Vascular) device following transfemoral transcatheter aortic ...